Clinical Trials
A list of clinical trials available in the Thoracic & Cardiovascular Surgery Department is provided below. These trials have been developed in collaboration with the Departments of Thoracic/Head & Neck Medical Oncology, Radiation Oncology and GI Medical Oncology. If you are interested in participating in one of these clinical trials, please call the Information Line toll-free at 1-800-MDA-06789 or visit the MD Anderson Clinical Trials site.
Lung Cancer
Study #: 2016-0737
Phase II Randomized Clinical Trials Comparing Immunotherapy plus Stereotactic Ablative Radiotherapy (I-SABR) versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR
NIH link: NCT03110978
Co-Principal Investigator: Mara Antonoff, M.D.
Phase II Randomized Clinical Trials Comparing Immunotherapy plus Stereotactic Ablative Radiotherapy (I-SABR) versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR
NIH link: NCT03110978
Co-Principal Investigator: Mara Antonoff, M.D.
Study #: 2017-0905
The role of multimodality management in risk-stratified patients with lung limited metastatic colorectal cancer
NIH link: NCT03599752
Principal Investigator: Mara Antonoff, M.D.
The role of multimodality management in risk-stratified patients with lung limited metastatic colorectal cancer
NIH link: NCT03599752
Principal Investigator: Mara Antonoff, M.D.
Study #: 2017-0228
NorthStar: Randomized Phase II trial of Local Consolidation Therapy (LCT) After Osimertinib for Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)
NIH link: NCT03410043
Co-Principal Investigator: Mara Antonoff, M.D.
NorthStar: Randomized Phase II trial of Local Consolidation Therapy (LCT) After Osimertinib for Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)
NIH link: NCT03410043
Co-Principal Investigator: Mara Antonoff, M.D.
Study #: 2017-0311
Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients with Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS
NIH link: NCT033918169
Co-Principal Investigator: Mara Antonoff, M.D.
Co-Principal Investigator: Mara Antonoff, M.D.
Co-Investigator: Stephen Swisher, M.D.
Study #: 2018-0366
Randomized phase II of Immunotherapy with Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)
NIH link: NCT03634241
Co-Principal Investigator: Mara Antonoff, M.D.
Co-Principal Investigator: Boris Sepesi, M.D.
Randomized phase II of Immunotherapy with Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)
NIH link: NCT03634241
Co-Principal Investigator: Mara Antonoff, M.D.
Co-Principal Investigator: Boris Sepesi, M.D.
Study #: 2019-0334
Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)
NIH link: NCT03802981
Principal Investigator: Mara Antonoff, M.D.
Principal Investigator: Mara Antonoff, M.D.
Study #: 2018-0598
BRIGHTSTAR: A Pilot Trial of Local Consolidative Therapy (LCT) with Brigatinib in Tyrosine Kinase Inhibitor-Naive ALK-Rearranged Advanced NSCLC
NIH link: NCT03707938
Collaborator: Reza Mehran, M.D.
Study #: 2020-0132
A Phase 3, Randomized,Single dose, Open-Label Studyto Investigate the Safety and Efficacy of OTL38 Injectionfor Intraoperative Imaging of Folate Receptor PositiveLung Nodules
NIH link: NCT04241315
Principal Investigator: David Rice, M.D.
Study #: ALLIANCEA151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) - Genetic Testing for Patients with Resectable or Resected Lung Cancer
NIH link: NCT02194738
Principal Investigator: Boris Sepesi, M.D.
Principal Investigator: Boris Sepesi, M.D.
Study #: 2016-0982
Phase II Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection, NEOSTAR/INDUCTION - Strategic Alliance: BMS
NIH link: NCT03158129
Co-Principal Investigator: Boris Sepesi, M.D.
Study #: 2018-1088
A Phase 2 Open-Label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I(>2 cm) to IIIA N0-1) Non-small Cell Lung Cancer (NeoCOAST)
NIH link: NCT03794544
Co-Principal Investigator: Boris Sepesi, M.D.
Study # : 2018-0301
Microwave Ablation Lung Malignancies
NIH link: NCT04430725
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2017-0311
Phase III trial of (LCT) after nivolumab and ipilimumab (LONESTAR)
NIH link: NCT03391869
Co-Principal Investigator: Stephen Swisher, M.D.
Neoadjuvant immune checkpoint blockade in Resectable Malignant Pleural Mesothelioma
Esophageal Cancer
Study #: 2016-0972
Chemoradiation +/- surgery vs systemic tx for esophageal or gastric ca with oligomets
NIH link: NCT03161522
Co-Principal Investigator: Wayne Hofstetter, M.D.
Study #: PA11-0891
Treatment Patterns, Outcomes, and Staging Deficiencies in cT2N0 Esophageal Cancer
Treatment Patterns, Outcomes, and Staging Deficiencies in cT2N0 Esophageal Cancer
Principal Investigator: Wayne Hofstetter, M.D.
Study #: PA12-0209
Pathologic and Molecular Predictors of Nodal Metastasis and Clinical Outcome in Surgically Resected Esophageal Adenocarcinoma
Principal Investigator: Wayne Hofstetter, M.D.
Study #: PA18-0463
Outcomes after Salvage Resection of Esophageal Squamous Cell Carcinoma
Principal Investigator: Wayne Hofstetter, M.D.
Outcomes after Salvage Resection of Esophageal Squamous Cell Carcinoma
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2019-1198
Distribution of lymph node metastases in esophageal carcinoma [TIGER]
Distribution of lymph node metastases in esophageal carcinoma [TIGER]
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2020-1199
Management of Nodal Recurrence after Curative Treatment of Esophageal Cancer
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2020-0193
Outcomes after Bimodality versus Trimodality Therapy for Esophageal Squamous Cell Carcinoma
Outcomes after Bimodality versus Trimodality Therapy for Esophageal Squamous Cell Carcinoma
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2020-0599
Risk Factors and treatment options for metachronic brain metastases after esophagectomy for esophageal cancer: a multicentric retrospective cohort study
Risk Factors and treatment options for metachronic brain metastases after esophagectomy for esophageal cancer: a multicentric retrospective cohort study
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2021-0565
Clinical Outcomes in Patients with Esophageal Cancer With Skip Lesions
Clinical Outcomes in Patients with Esophageal Cancer With Skip Lesions
Principal Investigator: Wayne Hofstetter, M.D.
Mesothelioma
Study #: SWOGS1619
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
NIH link: NCT03228537
Co-Principal Investigator: Boris Sepesi, M.D.
Neoadjuvant immune checkpoint blockade in Resectable Malignant Pleural Mesothelioma
NIH link: NCT03918252
Principal Investigator: Boris Sepesi, M.D.
Clinical Trials
Other departments like Thoracic Head & Neck Medical Oncology, Radiation Oncology and GI Medical Oncology may have available clinical trials open for lung cancer, esophageal cancer and mesothelioma.
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.